Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
US Army
Johnson and Johnson
Express Scripts
Accenture
Julphar
Harvard Business School
McKinsey

Generated: July 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205551

« Back to Dashboard

NDA 205551 describes TRIUMEQ, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TRIUMEQ profile page.

The generic ingredient in TRIUMEQ is abacavir sulfate; dolutegravir sodium; lamivudine. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.
Summary for 205551
Tradename:TRIUMEQ
Applicant:Viiv Hlthcare
Ingredient:abacavir sulfate; dolutegravir sodium; lamivudine
Patents:3
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 205551
Generic Entry Date for 205551*:
Constraining patent/regulatory exclusivity:
Dosage::
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 205551
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551 NDA ViiV Healthcare Company 49702-231 N 49702-231-13

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 600MG BASE;EQ 50MG BASE;300MG
Approval Date:Aug 22, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 12, 2018
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Sign UpPatent Expiration:Nov 14, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Oct 5, 2027Product Flag?YSubstance Flag?YDelist Request?

Expired US Patents for NDA 205551

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551-001 Aug 22, 2014 ➤ Sign Up ➤ Sign Up
Viiv Hlthcare TRIUMEQ abacavir sulfate; dolutegravir sodium; lamivudine TABLET;ORAL 205551-001 Aug 22, 2014 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Cantor Fitzgerald
Teva
Chubb
Deloitte
Johnson and Johnson
AstraZeneca
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.